These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30359047)

  • 1. Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment.
    Parker MA; Ochalek TA; Rose GL; Badger GJ; Sigmon SC
    Psychol Addict Behav; 2018 Dec; 32(8):956-960. PubMed ID: 30359047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.
    Oleskowicz TN; Ochalek TA; Peck KR; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2021 Mar; 220():108532. PubMed ID: 33508690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology-Assisted Buprenorphine Treatment in Rural and Nonrural Settings: Two Randomized Clinical Trials.
    Sigmon SC; Peck KR; Batchelder SR; Badger GJ; Heil SH; Higgins ST
    JAMA Netw Open; 2023 Sep; 6(9):e2331910. PubMed ID: 37755833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collecting Self-Reported Data on Dating Abuse Perpetration From a Sample of Primarily Black and Hispanic, Urban-Residing, Young Adults: A Comparison of Timeline Followback Interview and Interactive Voice Response Methods.
    Rothman EF; Heeren T; Winter M; Dorfman D; Baughman A; Stuart G
    J Interpers Violence; 2020 Jan; 35(1-2):100-126. PubMed ID: 27920359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials.
    Bergen AW; Baurley JW; Ervin CM; McMahan CS; Bible J; Stafford RS; Mudumbai SC; Saxon AJ
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder.
    Bhatraju EP; Radick AC; Leroux BG; Kim TW; Samet JH; Tsui JI
    Am J Drug Alcohol Abuse; 2023 Jul; 49(4):511-518. PubMed ID: 37369019
    [No Abstract]   [Full Text] [Related]  

  • 8. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and acceptability of a timeline follow-back method to assess opioid use, non-fatal overdose, and substance use disorder treatment.
    McCann NC; McMahan VM; Smith R; Majeski A; Johns SL; Kosakowski S; Wolfe S; Brennan S; Robinson M; Coffin PO; Walley AY
    Addict Behav; 2024 Jan; 148():107873. PubMed ID: 37801804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observations on the effects of buprenorphine and methadone on illicit drug use.
    Pesce AJ; Tran K; Krock K; Cua A; Thomas R
    J Opioid Manag; 2024; 20(3):193-195. PubMed ID: 39017611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent and retrospective reports of alcohol consumption across 30, 90 and 366 days: interactive voice response compared with the timeline follow back.
    Searles JS; Helzer JE; Rose GL; Badger GJ
    J Stud Alcohol; 2002 May; 63(3):352-62. PubMed ID: 12086136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
    Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
    JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.
    Mittal L; Suzuki J
    Subst Abus; 2017; 38(3):261-264. PubMed ID: 26672650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correspondence between Interactive Voice Response (IVR) and Timeline Followback (TLFB) reports of drinking behavior.
    Toll BA; Cooney NL; McKee SA; O'Malley SS
    Addict Behav; 2006 Apr; 31(4):726-31. PubMed ID: 15975732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
    Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
    Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
    Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
    Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.